Clinical Trial Update: A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis. [Phase 3]

View source ↗

Summary

A Phase 3 continuation study evaluating the effect of CellCept (mycophenolate mofetil) in patients with generalized myasthenia gravis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Myasthenia Gravis Generalised | Phase 3 | Status: COMPLETED